Survival Gains Seen With Assignment to Experimental Group in Cancer Trials
By Elana Gotkine HealthDay Reporter
TUESDAY, April 30, 2024 -- For patients with solid tumors, assignment to an experimental group in trials of investigational drugs yields significant survival gains, according to a review published online April 30 in the Annuals of Internal Medicine.
Renata Iskander, from McGill University in Montreal, and colleagues estimated progression-free survival and overall survival advantage of assignment to experimental groups in randomized trials of investigational drugs for six solid tumors. A total of 128 trials with 141 comparisons of a new drug and comparator were included in the sample, with 47,050 patients.
The researchers found that the pooled hazard ratio was 0.80 for progression-free survival, indicating significant benefit for patients in experimental groups and corresponding to a median progression-free survival advantage of 1.25 months. For overall survival, the pooled hazard ratio was 0.92, corresponding to a 1.18-month increase in survival. The absolute risk for a serious adverse event was 29.56 percent for comparator group patients compared with a 7.40 percent increase in risk for patients in experimental groups.
"Our findings provide a reassuring picture of current practices in drug regulation and research and can also help inform decisions about patient referral to trials, research policy, and consent discussions," the authors write.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted April 2024
Read this next
American College of Surgeons, Oct. 19-22
The annual meeting of the American College of Surgeons was held this year from Oct. 19 to 22 in San Francisco and attracted participants from around the world, including...
Restaging MRI Can Predict Survival With Rectal Cancer
TUESDAY, Oct. 29, 2024 -- Restaging magnetic resonance imaging (MRI) can predict organ preservation and survival with rectal cancer, according to a study published online...
ACS: Many Cancer Patients Face Lasting Financial Difficulties
MONDAY, Oct. 28, 2024 -- Many patients with cancer diagnoses experience lasting financial difficulties, according to two studies presented at the annual meeting of the American...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.